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 36 
Abstract 37 
The binding of three dinuclear platinum complexes, where the bridging ligand of the complexes is 38 
N,N’-(alkane-1,n-diyl)diisonicotinamide (n = 4, 6 or 8 for butane, hexane and octane, respectively) to 39 
the macrocycle para-sulphonatocalix[4]arene (sCX[4]) has been studied by 1H nuclear magnetic 40 
resonance (NMR) spectroscopy and molecular modelling. The NMR spectra show two important 41 
features, large upfield shifts of the methylene proton resonances of up to 1.8 ppm, which clearly 42 
places them within the shielding environment of the macrocycle’s cavity, and a loss of chemical 43 
symmetry of the metal complexes with extra resonances observed upon sCX[4] binding. Molecular 44 
models of the platinum-sCX[4] host-guest complexes show significant folding of the metal 45 
complexes’ aliphatic chain and a non-symmetrical interaction with the macrocycle. One side of the 46 
metal complexes forms three hydrogen bonds to sCX[4], whereas the opposite side of the metal 47 
complexes forms just one hydrogen bond, giving rise to the loss of chemical symmetry in the 1H NMR 48 
spectra. As the dinuclear platinum complexes are model anticancer drugs, the effect of sCX[4] 49 
binding was investigated in vitro in the human ovarian carcinoma cell line A2780 and its cisplatin-50 
resistant sub-line A2780cp70. Whilst the free metal complexes are a magnitude of order more active 51 
than cisplatin in the A2780 cell line, they are all highly cross-resistant with cisplatin in the A2780cp70 52 
line. Binding by sCX[4] has little affect on the metal complexes’ cytotoxicity in the sensitive cell line, 53 
but has a large effect in the resistant cell line. The two shortest metal complexes become less active 54 
when bound by sCX[4], whereas the longest metal complex becomes more cytotoxic.  55 
 56 
57 
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 58 
Introduction 59 
Platinum-based anticancer drugs remain an integral component of many chemotherapy regimens 60 
despite their toxic side-effects and the ability of cancers to develop drug resistance against them.[1] 61 
Multinuclear platinum drugs are a class of chemotherapy agent which have attracted interest in 62 
their ability to overcome resistance developed by tumours to many other anticancer agents. The 63 
lead drug in this class is BBR3464,[2] a trinuclear complex, which was developed as far as Phase II in 64 
clinical trials. Recently, two dinuclear derivatives have been investigated as potential drug 65 
candidates.[3] Whilst these drugs are significantly more cytotoxic than cisplatin, they are rapidly 66 
degraded in vivo resulting in very little of the drug reaching tumours. Our group is interested in the 67 
use of macrocycles as protective delivery vehicles for multinuclear platinum drugs with a focus on 68 
the cucurbituril,[4, 5] cyclodextrin[6] and calixarene[6, 7] families of cavitands. One of the key 69 
benefits of macrocycle binding to platinum drugs is that their encapsulation confers steric 70 
protection, which slows or prevents the drug’s degradation by biological thiols like glutathione,[8-71 
11] or sequestration by proteins like human serum albumin.[12-14]  72 
 73 
Calixarenes are a family of macrocycles made from a hydroxyalkylation reaction between an 74 
aldehyde and phenol.[15] The resultant molecules, that generally contain 4, 6, 7, 8 or 9 subunits, 75 
form bowl shaped structures with a hydrophobic pocket and a extensively hydrogen bonded 76 
network of hydroxyl groups at its base.[15] The application of calixarenes to drug delivery stems 77 
from their ability to form host-guest complexes with a range of small molecule drugs and biological 78 
molecules.[16, 17] Such complexes are stabilised by hydrophobic effects and/or ion-dipole 79 
interactions or hydrogen bonds.  80 
 81 
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Native calixarenes are poorly soluble in aqueous solutions but functionalisation with sulphonate 82 
groups yields derivatives that are highly soluble.  Para-sulphonated calixarenes (Figure 1), 83 
particularly the macrocycle made of four subunits (sCX[4]), have demonstrated many applications in 84 
drug delivery including: improved drug solubility, chemical stability, bioavailability, biodistribution 85 
and transport, and/or elimination of drug polymorphism in the solid state.[16, 18, 19] As an 86 
excipient for drugs, sCX[4] also displays relatively little cytotoxicity or toxicity in vivo.[20] 87 
 88 
Figure 1. The chemical structure of para-sulphonatocalix[4]arene (sCX[4]), a molecular model 89 
showing sCX*4+’s bowl-shaped structure, and the chemical structure of the dinuclear platinum 90 
complexes used in this study; n = 1, 2 or 3. Counter ions for both molecules have been omitted. 91 
 92 
Previously we have shown that sCX[4] is capable of forming host-guest complexes with different 93 
types of platinum anticancer complexes, including dinuclear agents.[6, 7] In our recent study 94 
involving a dinuclear platinum complex with a rigid bridging linker, however, we found that the 95 
sCX[4] bound the platinum complex in a side-on manner and provided no barrier to drug 96 
degradation.[7] Despite this, the strong association constant, and the ease with which sCX[4] can be 97 
functionalised with cancer targeting groups, made us hypothesise that the macrocycle may still be 98 
useful as a platinum drug delivery vehicle. The sulphonate groups of sCX[4] can readily be 99 
functionalised with groups which can be used to actively target tumours. A recent example includes 100 
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folate, a vitamin essential to cell growth,[21] and which was conjugated to sCX[4].[22] As such, we 101 
are interested in developing actively targeted sCX[4] derivatives which can be used to deliver 102 
multinuclear platinum drugs to cancers. 103 
 104 
As a first step in our development of targeted calixarene-based delivery vehicles, in this paper we 105 
have investigated the binding of sCX[4] to a new group of dinuclear platinum complexes which have 106 
been shown to be up to 10-fold more active than cisplatin.[23] Their binding was examined by 1H 107 
and DOSY NMR from which molecular models were developed. The effect of sCX[4] on the 108 
cytotoxicity of the dinuclear platinum complexes was evaluated using in vitro growth inhibition 109 
assays with the human ovarian carcinoma cell line A2780 and its cisplatin-resistance sub-line 110 
A2780cp70. 111 
 112 
Experimental 113 
Materials. Para-sulphonatocalix[4]arene, diethyl ether, triethylamine, transplatin, D2O (99.9%), 114 
isonicotinic acid and 1,6-diaminohexane were purchased from Sigma Aldrich. T3P® was purchased 115 
from Alfa Aesar. The metal complexes (1), (2) and (3) were made following a published method [23]. 116 
The characterisation data for 2 has not previously been reported and is given below. 117 
 118 
Characterisation data for the ligand of complex (2). 1H NMR (d6-DMSO, ppm): 8.72 (t), 8.70 (d, J = 119 
4.4 Hz), 7.72 (d, J = 4.6 Hz), 1.53 (m), 1.34 (m). 13C NMR (d6-DMSO): 165.1, 151.8, 142.1, 121.7, 29.45, 120 
26.74. ESI-MS [M+H]+ expected: 327.18 m/z, found: 327.60 m/z. Elemental analysis C18H22N4O2. 121 
Expected: C, 66.24; H, 6.79; N, 17.17%; Found: C, 65.85; H, 6.71; N, 16.84%. 122 
 123 
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Characterisation data for complex (2). 1H NMR (D2O, ppm): 8.97 (d, J = 7.0 Hz), 8.96 (t), 7.78 (d J = 124 
6.6 Hz), 3.38 (m), 1.61 (m), 1.38 (m). 195Pt NMR (D2O, ppm): -2301. ESI-MS [M+H]
+ expected: 855.16 125 
m/z, found: 855.20; [M]2+ expected: 427.08 m/z, found: 428.47 m/z. Elemental analysis 126 
C18H34Cl4N8O2Pt2.3H2O. Expected: C, 22.05; H, 4.11; N, 11.43%. Found: C, 21.93; H, 4.09; N, 11.21%. 127 
 128 
1H NMR. One dimensional NMR spectra were obtained in D2O on a JEOL JNM-LA400 referenced 129 
internally to the solvent peak at 4.78 ppm. Diffusion ordered spectroscopy experiments in D2O were 130 
obtained on a Bruker Avance 400 using 600 µL of sample in a Wilmad NMR tubes rated for 400-500 131 
MHz use. The pulse sequence used was the standard DOSYsequence provided by Bruker and 132 
analysed with the Bruker relaxation software using a non-linear least-squares fit of the data to the 133 
equation: I = e(γ2g2δ2D(Δ-δ/3). Each diffusion cofficient was determined using a Δ of 80 ms, a δ of 5 134 
ms,, and recycle time of 5 s and at a fixed temperature of 25 oC. 135 
 136 
Molecular modelling. Calculations were performed on a dual-Xeon processor, workstation using 137 
the DMol3 (Delley, Delley) program in Accelrys’ Materials Studio (Accelrys). Individual geometry 138 
optimisations for the three platinum complexes were undertaken at the LDA PWC level 139 
(Perdew) using a DND basis set (Double Numerical plus d-functions on all non-hydrogen atoms) 140 
in order to locate structurally stable conformers. Bond distances were determined using the 141 
measurement tool of the modelling software program: Accerlys Discovery Studio 3.1 visualizer.  142 
 143 
In vitro growth assays. The cytotoxicity of the metal complexes and the platinum-sCX[4] host-guest 144 
complexes were conducted using MTT-based in vitro growth inhibition assays using the A2780 and 145 
A2780/cp70 human ovarian carcinoma cell lines as previously described [24]. The A2780 and 146 
A2780cp70 ovarian cancer lines were grown in RPMI media containing 10% foetal calf serum, 147 
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penicillin streptomycin and L-glutamate in a 5% CO2 atmosphere. The cells were trypsinised, counted 148 
and adjusted to 500-1000 cells per well in 96 well plates). Metal complex/sCX[4] stock solutions 149 
were diluted with RPMI to prepare a dilution series based on the total platinum concentration (0.1 – 150 
100 μM). 10 μL aliquots were taken from these solutions and added in triplicate to each well along 151 
with RPMI only. The plate was then cultured for 24h, after which MTT (50 L of a 5 mg mL-1 solution) 152 
was added to the 200 L of medium in each well and the plates were incubated at 37 oC for 4 h in 153 
the dark. Medium and MTT were then removed and the MTT-formazan crystals dissolved in 200 L 154 
DMSO. Glycine buffer (25 L per well, 0.1 M, pH 10.5) was added and the absorbance measured at 155 
570 nm in a multiwell plate reader. 156 
 157 
Results and discussion 158 
NMR. Proton NMR is possibly one of the most powerful techniques for examining the host-guest 159 
complexes of sCX[4]. The large changes in the chemical shift of guest resonances for metal complex 160 
protons located inside the sCX[4] cavity due to shielding effects can give information of binding 161 
location, depth and orientation as well as an indication of the exchange kinetics.  162 
 163 
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 164 
Figure 2. 1H NMR spectra of (a) free complex (1), (b) sCX[4] and (c) the 1:1 host-guest complex 165 
showing the additional metal complex (1) resonances and the large upfield shift of the metal 166 
complex methylene resonances due to their shielding within the sCX[4] cavity. 167 
 168 
In the 1H NMR spectra each free metal complex (1-3) displays two doublet resonances at 8.95 and 169 
7.76 ppm and either two or three resonances, representing the methylene protons, between 1.2 and 170 
3.4 ppm (Figure 2). Free sCX[4] has three resonances, the aromatic protons are all magnetically 171 
equivalent and are observed as a singlet resonance at 7.52 ppm. The sCX[4] methylene proton 172 
resonance is observed at 3.29 ppm, and despite solvent exchange, freshly prepared samples have a 173 
broad hydroxyl resonance at 3.95 ppm. 174 
 175 
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Upon the addition of one equivalent of metal complex (1-3) to sCX[4] at ~1 mM in D2O a white 176 
precipitate occurs, indicating the immediate formation of a host-guest complex. Despite this, enough 177 
complex remains in solution to obtain 1H NMR spectra. The binding of sCX[4] has a marked effect on 178 
the chemical shifts of the metal complex resonances. For all three metal complexes the aromatic 179 
protons are now no longer chemically equivalent and four doublet resonances are observed 180 
between 7.5 and 8.95 ppm (Figure 2). For the aliphatic resonances there are very large changes in 181 
their chemical shift and the observation of additional peaks in the 1H NMR spectra when the 182 
methylene protons become no longer chemically equivalent upon binding. In some cases there is 183 
significant broadening of the metal complex resonances as the host-guest complex goes into 184 
intermediate exchange kinetics on the NMR timescale. 185 
 186 
For complex (1), the free metal complex has two aliphatic resonances at 3.40 and 1.66 ppm. Upon 187 
addition of sCX[4], as well as the additional two aromatic resonances, four aliphatic resonances are 188 
observed at 2.13, 1.22, -0.13 and -0.18 ppm (see Figure 2). For complex (2) four aromatic resonances 189 
are again observed and whilst free complex (2) has three aliphatic resonances at 3.4, 1.6 and 1.4 190 
ppm, upon binding by sCX[4] five resonances are observed for the methylene protons. Two very 191 
broad peaks at 2.54 and 0.26 ppm, and three sharp resonances at 2.15, 2.03 and 1.17 ppm. Finally 192 
for complex (3), again the four aromatic resonances are observed upon sCX[4] binding and in the 193 
aliphatic region, there are numerous very broad and overlapping resonances between 0.2 and 3.1 194 
ppm.  195 
 196 
Overall, the very large changes in chemical shift are consistent with the binding of other platinum 197 
complexes to sCX[4] and clearly places the methylene chain of the three metal complexes within the 198 
sCX[4] cavity.[6, 7] Importantly, the extra metal complex resonances observed in both the aromatic 199 
10 
 
and aliphatic regions of the NMR indicate that the metal complexes are changing 200 
shape/conformation upon binding to the macrocycle in such a way that the two sides of the 201 
complexes are no longer magnetically equivalent.  202 
 203 
The binding of complex (1) to sCX[4] was also examined using 1H diffusion ordered NMR 204 
spectroscopy (DOSY). The large amount of precipitate upon binding of complexes (2 and 3) excluded 205 
their analysis by DOSY. The diffusion coefficient of the free metal complex is 6.73 (± 0.37) x 10-10  206 
m2s-1. Upon binding by sCX[4] the metal complex’s diffusion coefficient drops to 5.55 (± 0.13) x 10-10 207 
m2s-1, which is consistent with an increase its hydrodynamic radius as the host-guest complex is 208 
formed. The diffusion coefficient of free sCX[4] has previously been determined as 3.21 x 10-10  m2s-1 209 
[6]. 210 
 211 
Molecular modelling. To further understand the binding of the three metal complexes to sCX[4], 212 
molecular models of each host-guest complex were generated using the results of the 1H NMR 213 
experiments which indicated placement of the metal complexes’ aliphatic chain centre most within 214 
the macrocycle cavity (Figure 3). 215 
 216 
The models all indicate significant folding of the methylene chains. Each linker is considerably longer 217 
than the diameter of the sCX[4] cavity, and so the linker folds to maximise the hydrophobic 218 
interactions between itself and the inner surface of the macrocycle. The result is a significant 219 
shortening of the end-to-end length of all three complexes (Table 1). 220 
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Table 1. Relevant bond lengths of the free metal complexes and the metal complexes upon folding to form the sCX[4] host-guest complexes. 221 
Metal complex state 
Bond lengths (Ǻ) 
Complex (1) Complex (2) Complex (3) 
NH—NH O—O Pt—Pt NH—NH O—O Pt—Pt NH—NH O—O Pt—Pt 
Free complex 6.23 10.35 19.9 8.75 12.8 22.2 11.3 15.3 24.5 
Host-guest complex 5.90 5.50 17.9 7.01 6.88 19.1 9.09 7.73 20.5 
 222 
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The Pt-to-Pt length of complex (1) shortens by 11%, complex (2) by 16% and complex (3) by 20%. 223 
Interestingly, for the free metal complexes the end-to-end lengths of the amide-nitrogen atoms are 224 
always shorter than the end-to-end lengths of the amide-oxygen atoms, but when binding to sCX[4] 225 
the folding of the linker causes the groups to rotate in such a way that the end-to-end lengths of the 226 
amide-oxygens are always shorter than the amide-nitrogens. 227 
 228 
Figure 3. Energy minimised models of the three dinuclear platinum host-guest complexes with the 229 
sCX[4] macrocycle, showing from bottom to top complexes (1-3), respectively. The models show the 230 
significant folding of the metal complexes’ aliphatic chains to maximise hydrophobic effects with the 231 
inner surface of the macrocycle. Counter ions are not shown. 232 
 233 
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The host-guest complex is stabilised not just by hydrophobic effects but also by intra- and 234 
intermolecular hydrogen bonds (Figure 4, Table 2). Four intramolecular OH—O hydrogen bonds 235 
stabilise the base of the sCX[4] as is typical of this macrocycle. Four intermolecular hydrogen bonds 236 
are observed between the metal complexes and sCX[4]; three of these hydrogen bonds (N—O, NH—237 
O and O—O) are from one side of the metal complexes with the other hydrogen bond  (NH—O) 238 
observed from the other side of the metal complexes.  239 
 240 
Figure 4. The molecular model of complex (3) and sCX[4] showing the four hydrogen bonds that hold 241 
the bottom of the calixarene macrocycle together (dashed green lines) and the four intermolecular 242 
hydrogen bonds that stabilise the host-guest complex (solid green lines).  243 
 244 
Table 2. Hydrogen bond lengths of the metal complex—sCX[4] host-guest complexes. 245 
Hydrogen bond 
Length (Ǻ) 
Complex (1) Complex (2) Complex (3) 
NH—O (1) 1.76 1.74 1.76 
NH—O (2) 1.86 1.74 2.39 
N—O 2.96 2.88 3.08 
O—O 2.86 2.84 3.07 
 246 
 247 
14 
 
Cytotoxicity. As the metal complexes were designed as potential anticancer drugs[23] and the 248 
ultimate goal is the use of sCX[4] as a targeted drug delivery vehicle, the cytotoxicity of the free 249 
metal complexes and their host-guest complexes with sCX[4] were examined using in vitro growth 250 
inhibition assays. Their IC50 (the concentration of metal complex required to inhibit cell growth by 251 
50%) was compared to the current platinum standard: cisplatin. All three of the metal complexes are 252 
a magnitude of order more active than cisplatin in the sensitive human ovarian carcinoma cell line 253 
A2780 (Table 3). Within the error of the experiments, binding to sCX[4] does not affect the 254 
cytotoxicity of the shortest (1) and longest (3) of the metal complexes. For complex (2) binding by 255 
sCX*4+ appears to slightly increase the metal complex’s cytotoxicity.  256 
 257 
Table 3. The in vitro cytotoxicity of the three platinum complexes with, and without, one equivalent 258 
of sCX[4] in the human ovarian carcinoma cell line A2780 and its cisplatin resistant sub-line 259 
A2780cp70. Rf is the resistance factor and is determined by the IC50 in the resistant line divided by 260 
the IC50 in the sensitive line. 261 
Metal 
complex 
IC50  
Rf 
A2780 A2780cp70 
Cisplatin 0.22 ± 0.03 3.82 ± 0.21 17.4 
sCX[4]a >1500 1500 n/a 
1 0.029 ± 0.012 4.94 ± 0.09 170 
1—sCX[4] 0.030 ± 0.004 12.41 ± 1.08 414 
2 0.041 ± 0.005 2.72 ± 0.77 66 
2—sCX[4] 0.026 ± 0.004 3.75 ± 0.50 144 
3 0.028 ± 0.011 2.84 ± 0.15 101 
3—sCX[4] 0.052 ± 0.018 0.576 ± 0.025 11.1 
 a. Data taken from reference [7]. 262 
 263 
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The A2780cp70 is a sub-line of A2780 which has been developed to express resistance to cisplatin 264 
treatment. This is observed by the much higher cisplatin IC50 in this cell line, 3.82 µM, compared with 265 
the sensitive cell line, 0.22 µM. The resistance factor (Rf) is a measure of a drug’s activity in the 266 
matched cell lines, with an Rf value of 1 or lower indicating an ability to circumvent resistance.  All 267 
three metal complexes lose their activity in the A2780cp70 cell line and do not overcome resistance. 268 
There does however appear to be a general trend demonstrating that the longer the length of the 269 
metal complex, the more active it is in the resistant cell line to the extent that the host-guest 270 
complex of complex (3) and sCX[4] has a smaller resistance factor than cisplatin. 271 
 272 
These in vitro assays are used only as an initial cytotoxicity screen as we have discovered over the 273 
last five years that the total effect of delivery vehicles on the activity of platinum anticancer 274 
complexes can only be properly evaluated in vivo.[25] This is due to the nature of the in vitro assay 275 
which has relatively short drug exposure times, grows cancer cells as monolayers rather than solid 276 
tumours and does not allow for the dynamics of drug distribution and uptake in a living animal. In 277 
many cases drug delivery vehicles have no effect on metal complex cytotoxicity in vitro, but in 278 
several cases the addition of the delivery vehicles results in significantly improved cytotoxicity in 279 
vivo.[25] As such, the results obtained in this study provide preliminary cytotoxicity data, but only in 280 
vivo experiments can definitively examine the effect on sCX[4] on the metal complexes. 281 
 282 
Conclusions 283 
In this work the formation of host-guest complexes of three dinuclear platinum complexes with the 284 
bowl-shaped macrocycle para-sulphonatocalix[4]arene has been studied. All three complexes bind 285 
the macrocycle so that the aliphatic chain of their bridging linker resides in the cavity. Such binding 286 
results in significant folding of the metal complexes such that their end-to-end length is reduced by 287 
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as much as 20%. Binding is stabilised by hydrophobic forces between the metal complexes’ bridging 288 
ligand and the inner surface of the macrocycle’s cavity, and four intermolecular hydrogen bonds; 289 
three on one side of the metal complexes and one on the opposite side. The result is a loss of 290 
chemical symmetry of the metal complex which is observed in the 1H NMR spectra. Binding of the 291 
macrocycle to the metal complexes has little, to no, effect on their in vitro cytotoxicity in the human 292 
ovarian carcinoma cell line A2780, but a significant effect in the cisplatin-resistant cell line 293 
A2780cp70. The results of this work provide important knowledge on the nature of the host-guest 294 
complex formation of flexible dinuclear platinum complexes and can now be used to develop more 295 
advanced drug delivery vehicles where sCX[4] can be conjugated with tumour targeting groups to 296 
better deliver multinuclear platinum drugs in chemotherapy. 297 
 298 
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